Core Viewpoint - The company, Giant Bio (2367.HK), experienced a significant intraday stock increase of 13.72%, reaching HKD 43.92, following the announcement of receiving a medical device registration certificate from the National Medical Products Administration of China for its recombinant type I α1 collagen freeze-dried fiber product [1] Group 1: Product Approval - The company’s wholly-owned subsidiary, Shaanxi Giant Bio Technology Co., Ltd., received the medical device registration certificate for its recombinant collagen product [1] - This product is designed for facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] - It is noted as the first recombinant type I natural sequence collagen injectable product approved in China, showcasing the company's core competencies in technology research and development [1] Group 2: Market Opportunities - The approval of this product enriches the company's product portfolio and presents new opportunities for business development in the skin rejuvenation market [1]

Market Performance - The Hang Seng Healthcare Index decreased by 2.71% as of October 23, 2025, with mixed performance among constituent stocks [2] - The Hang Seng Medical ETF (513060) fell by 2.41%, with a latest price of 0.65 CNY, but has seen a 3.42% increase over the past three months [2] - The Hong Kong Stock Connect Innovative Drug Selection Index dropped by 3.70%, with the Hong Kong Innovative Drug Selection ETF (520690) down by 3.26% [4][5] - The CSI Pharmaceutical 50 Index declined by 0.95%, while the Pharmaceutical 50 ETF (159838) decreased by 0.96% [6] Liquidity and Trading Activity - The Hang Seng Medical ETF had a turnover of 11.25% and a trading volume of 763 million CNY, indicating active market participation [2] - The Hong Kong Innovative Drug Selection ETF recorded a turnover of 21.44% with a trading volume of approximately 98.5 million CNY [5] - The Pharmaceutical 50 ETF had a turnover of 1.67% and a trading volume of 2.71 million CNY [6] Key Events and Trends - The flu season has started early, leading to a rise in flu-related stocks, with companies like Hendi Pharmaceutical and Duori Pharmaceutical seeing significant gains [7] - The ongoing ESMO (European Society for Medical Oncology) conference has heightened interest in Chinese pharmaceutical companies, showcasing clinical data from firms like Heng Rui Pharmaceutical and Ke Long Bo Tai [7] - The collaboration between Sinopharm and Takeda is expected to enhance foreign investment confidence in Chinese innovative drug assets [7] Industry Insights - The Chinese innovative drug sector is accelerating its international presence, with 135 licensing-out transactions recorded from January to October 17, 2025, totaling over 102.9 billion USD [7] - The ESMO conference highlighted 23 LBA studies led by Chinese scholars, demonstrating the global competitiveness of China's innovative drug pipeline [7] - The aging population is increasing the demand for chronic disease treatments, while the optimization of the medical insurance payment system and AI technology applications are injecting new vitality into the industry [8] ETF Overview - The Hang Seng Medical ETF has a current scale of 6.865 billion CNY, ranking in the top third among comparable funds [8] - The Hong Kong Innovative Drug Selection ETF reached a new high with a scale of 468 million CNY [10] - The Pharmaceutical 50 ETF tracks the top 50 pharmaceutical companies in China, with the top ten stocks accounting for 59.46% of the index [11]

Core Viewpoint - The approval of the recombinant type I α1 collagen freeze-dried fiber product marks a significant milestone for the company, enhancing its competitive edge in the skin rejuvenation market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate from the National Medical Products Administration of China for the recombinant type I α1 collagen product [1] - This product is the first recombinant natural sequence collagen injectable approved in China, indicating a breakthrough in the company's product offerings [1] Group 2: Market Opportunities - The approval of this product will enrich the company's product categories and provide new opportunities for business development in the skin rejuvenation market [1] - The company plans to gradually launch and promote this product in accordance with its business strategy, leveraging existing products, brands, and channels to enhance consumer experience [1] Group 3: Competitive Position - The approval reflects the company's core competencies in technology research and development as well as industrialization [1] - The company aims to solidify its leading position in the health and beauty sector through this new product offering [1]

Core Viewpoint - The company has received a medical device registration certificate for its recombinant type I α1 collagen freeze-dried fiber product, marking a significant advancement in its product offerings and potential market opportunities in the skin rejuvenation sector [1] Group 1: Product Approval - The product is the first recombinant type I natural sequence collagen injectable approved in China, showcasing the company's technological research and development capabilities [1] - The approval was granted through a joint review of device and drug assessments, highlighting the regulatory efficiency [1] Group 2: Market Opportunities - The new product will enhance the company's product portfolio and provide new opportunities for business development in the skin rejuvenation market [1] - The company plans to gradually launch and promote the product in accordance with its business strategy, aiming to offer a diverse experience to consumers [1] Group 3: Competitive Position - The approval reinforces the company's leading position in the health and beauty sector, allowing it to strengthen its existing products, brands, and channels [1]

Core Viewpoint - The approval of the recombinant type I α1 collagen freeze-dried fiber product by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its competitive edge in the skin rejuvenation market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the recombinant type I α1 collagen freeze-dried fiber product [1] - This product is the first recombinant type I natural sequence collagen injectable product approved in China, indicating a breakthrough in the industry [1] Group 2: Market Opportunities - The approval reflects the company's core competencies in technology research and development, as well as industrialization [1] - The new product will diversify the company's product offerings and create new opportunities for business development in the skin rejuvenation market [1] Group 3: Future Plans - The company plans to gradually launch and promote the product according to its business strategy [1] - There will be a focus on collaboration with existing products, brands, and channels to provide consumers with a more diverse experience [1] - The company aims to strengthen its leading position in the health and beauty sector [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 自願性公告 本公告乃由巨子生物控股有限公司（「本公司」）自 願 作 出。 本 公 司 欣 然 宣 布，本 公 司 全 資 子 公 司 陝 西 巨 子 生 物 技 術 有 限 公 司 於 今 日 收 到 中 國國家藥品監督管理局頒發的關於重組I型α1亞型膠原蛋白凍幹纖維產品（「本 產 品」）的《中 華 人 民 共 和 國 醫 療 器 械 註 冊 證》（註 冊 證 編 號：國 械 註 准20253132049）。 本 產 品 以 重 組 膠 原 蛋 白 為 主 要 成 分，用 於 面 部 真 皮 組 織 填 充 以 糾 正 額 部 動 力 性 皺 紋，包 括 眉 間 紋、額 頭 紋 和 魚 尾 紋。 本產品是中國首個重組I型 天 然 序 列 膠 原 蛋 白 面 部 注 射 劑 產 品，通 過 器 審 與 藥 審 聯 合 審 評 正 式 獲 批。本 產 ...

Group 1 - The Hang Seng Index fell by 0.09%, down 24 points, closing at 25,757 points, while the Hang Seng Tech Index dropped by 0.81% [1] - The trading volume in Hong Kong stocks reached HKD 134.8 billion in the morning session [1] - Chinese banks continued their recent upward trend, with Postal Savings Bank (01658) rising over 3%, supported by multiple catalysts for bank revaluation according to Morgan Stanley [1] - China Hongqiao (01378) increased by 3.07%, demonstrating confidence through large-scale continuous buybacks amid emerging disruptions in the aluminum industry [1] - China National Heavy Duty Truck Group (03808) rose by 1.49%, with September heavy truck exports reaching a record high of 15,000 units, and annual exports expected to exceed 150,000 units [1] - Giant Bio (02367) rebounded over 5% after the controlling shareholder increased holdings by 500,000 shares, with Citigroup stating that the market overreacted to pre-sale performance [1] Group 2 - Chip stocks continued to decline, with the U.S. planning to restrict key software exports, while institutions are optimistic about the acceleration of domestic self-sufficiency. Hua Hong Semiconductor (01347) fell by 6%, and Shanghai Fudan (01385) dropped by 6.43% [1] - The Hang Seng Innovation Drug Index plummeted by 4%, with constituents such as Jiajian Pharmaceutical-B (02617) and CSPC Pharmaceutical Group (01093) both declining over 5% [1] - Apple-related stocks experienced significant declines, with Q Technology (01478) dropping nearly 4% and GoerTek (01415) falling by 3.3%. Notably, renowned Apple analyst Ming-Chi Kuo indicated that iPhone Air demand is below expectations, leading the supply chain to reduce shipments and production capacity [1] - China Aluminum International (02068) fell over 8%, as the market focused on potential transactions involving China Aluminum and Rio Tinto, given the company's extensive overseas operational experience [1] Group 3 - Guanghetong (00638) saw a decline of over 8% on its second day of trading, having dropped nearly 20% from its IPO price [2]

Group 1: Hong Kong Stock Market Highlights - China Hongqiao (01378) rose over 2% as the company continued its share buyback, spending HKD 7.5941 million to repurchase 300,000 shares [1] - Sands China (01928) increased by over 3% following its parent company Las Vegas Sands Corp.'s announcement of a 2.7% rise in adjusted property EBITDA for Q3 [1] - Aluminum Corporation of China International (02068) fell over 11% amid market focus on potential transactions involving Chalco and its rich overseas operational experience [1] - Giant Bio (02367) gained over 6% as its controlling shareholder increased holdings by 500,000 shares, with Citigroup suggesting the market overreacted to pre-sale performance [1] - Li Ning (02331) rose over 6% as the brand announced its entry into Meituan Flash Purchase on October 20 [1] - Semiconductor stocks continued to decline, with Huahong Semiconductor (01347) down over 6% and SMIC (00981) down nearly 1%, as the U.S. plans to restrict key software exports [1] - China National Heavy Duty Truck Group (03808) increased over 2% with September heavy truck exports reaching a record high of 15,000 units, expecting annual exports to exceed 150,000 units [1] Group 2: Steel and Banking Sector Performance - Steel stocks faced declines, with Maanshan Iron & Steel (00323) down over 3% and Angang Steel (00347) down over 2%, as seasonal demand fell short of expectations [2] - Chinese banks continued to rise, with Postal Savings Bank (01658) up over 3% and Agricultural Bank of China (01288) nearly 1%, supported by multiple catalysts for bank revaluation according to Morgan Stanley [2] - Gold stocks continued to decline, with China Silver Group (00815) down over 1% and Lingbao Gold (03330) down over 2%, following a significant drop in gold prices [2] Group 3: U.S. Stock Market Highlights - Mattel (MAT.US) fell 2.76% after reporting a 6% year-over-year decline in Q3 sales to USD 1.74 billion, below market expectations [3] - NIO (NIO.US) rose 0.59% as its L90 model achieved a record weekly delivery volume, with production capacity up 50% from the previous month [3] - Intuitive Surgical (ISRG.US) surged 13.89% due to a 22.9% year-over-year revenue increase driven by demand for its da Vinci robotic systems for minimally invasive surgeries [3] - Texas Instruments (TXN.US) dropped 5.60% as its Q4 revenue and profit forecasts fell short of Wall Street expectations [3] - Weibo (WB.US) increased 5.22% as it plans to announce its Q3 2025 financial results in mid-November, although its advertising business may face multiple pressures [3] - Barclays (BCS.US) rose 4.41% despite a 7% year-over-year decline in pre-tax profit for Q3 [4] - Google (GOOGL.US) increased 0.49% as it negotiates a cloud computing service contract with Anthropic, potentially worth several billion USD [4]

每经AI快讯，巨子生物(02367.HK)反弹逾8%，截至发稿，涨8.49%，报41.9港元，成交额4亿港元。 ...

Core Viewpoint - Juzi Bio (02367) has seen a rebound of over 8%, with a current price of HKD 41.9 and a trading volume of HKD 400 million, following the announcement of share purchases by its controlling shareholder, Juzi Holding [1] Group 1: Shareholder Activity - Juzi Holding purchased 500,000 shares of Juzi Bio on the announcement date, amounting to approximately HKD 19.3 million [1] - Since the disclosure of the share purchase plan on June 9, 2025, Juzi Holding has cumulatively acquired 3.666 million shares, investing a total of about HKD 178 million [1] - Following these purchases, Juzi Holding's shareholding increased to 585 million shares, representing 54.61% of the company's total issued shares, with intentions to further increase holdings based on market conditions and regulatory requirements [1] Group 2: Market Analysis - Citigroup recently released a report indicating that the market's reaction to Juzi Bio's pre-sale performance decline during the Double 11 event, particularly in relation to Li Jiaqi's live-streaming sales, is exaggerated [1] - Although Li Jiaqi's live-streaming sales trends are significant indicators for Double 11 performance, the contribution from other KOLs and the company's own live-streaming efforts has sharply increased, reducing Li Jiaqi's relative impact [1] - Despite the competitive landscape, there has been no negative feedback from customers regarding the company's products or brand, and Citigroup anticipates a recovery in sales for Juzi Bio in the fiscal year 2026, given the low base this year, suggesting that the company's valuation remains attractive [1]